Press release – For immediate release – 5:45 pm CEST
Disclosure of total number of voting rights and number of shares in the capital as of March 31, 2025, pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.
| Total number of shares | 18,859,216 |
| Number of real voting rights* (excluding treasury shares**) | 18,785,889 |
| Theoretical number of voting rights*(including treasury shares**) | 18,836,016 |
(**) pursuant to article 223-11 of the AMF’s General Regulations
Pioneering innovative imaging services and Software as Medical Devices, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median’s offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis™, an AI/ML tech-based suite of software as medical devices (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S. and China, trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is also eligible for the French SME equity savings plan scheme (PEA-PME). For more information, visit